Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072098 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
A Phase 1 study, sponsored by Max Sung.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00072098: Clinical Trial Phase 1 study, sponsored by Max Sung.
NCT00072098 is a Phase 1 study that was terminated before completion, run by Max Sung. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072098, a Phase 1 study, was terminated before completion, sponsored by Max Sung.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases secondary to colorectal cancer.
Interventions
- BIOLOGICAL interleukin-12 gene
- BIOLOGICAL adenovirus vector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2003-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072098
The ClinicalTrials.gov registry entry for NCT00072098 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Max Sung, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which interleukin-12 gene is the first listed.
NCT00072098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072098 about?
NCT00072098 is a clinical study titled "Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer". RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12 gene when injected into the tumors of patients with liver metastases sec...
What is the current status of trial NCT00072098?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2003-09. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00072098?
The interventions under investigation include: interleukin-12 gene (BIOLOGICAL), adenovirus vector (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072098?
This trial is sponsored by Max Sung, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.